Elanco Animal Health Posts 11% Revenue Growth, Raises 2026 Outlook
Elanco Animal Health reported Q3 2026 revenue of $1.265B, up 11% YoY, and adjusted EPS of $0.27. Net income was $18M, reversing a loss from the prior year. The company raised its 2026 outlook for revenue, adjusted EBITDA, and adjusted EPS. Key products like Zenrelia and Credoil Quattro drove growth, with market share gains in the U.S. and Europe.
How this was made
The 30-second read
Why it matters
The guidance lift is a material, first‑report event that can drive the stock higher.
Market read
The earnings beat and guidance raise provide a fresh catalyst for ELAN, likely influencing sector peers.
What to watch
Potential supply‑chain constraints or regulatory risks could temper the upside.
Background
Elanco's Q3 2026 earnings beat expectations and the company upgraded its full‑year guidance for revenue, adjusted EBITDA, and EPS.
Ticker impact
Elanco Animal Health reported Q3 2026 results and raised its full-year 2026 revenue and earnings guidance.
likely upward pressure as investors price in higher revenue and EPS forecasts
The company posted a swing to profit and increased its 2026 outlook, which is new information that can move the stock.
Market effects
Improves outlook for the animal health sector, potentially lifting peers.
U.S. animal health and broader agribusiness stocks may see modest gains.
Limited to markets with exposure to livestock and pet health products.
Counterpoint
If the guidance raise is already priced in, the stock may face a short‑term pullback.
Key entities
- companyElanco Animal Health Inc.
U.S. animal health and veterinary pharmaceutical company.
